

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (KL-47) TOZORAKIMAB

PRONUNCIATION toe" zoe ra' ki mab

THERAPEUTIC CLAIM Treatment of COPD, asthma, atopic dermatitis, diabetic kidney disease

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human interleukin 33) (human monoclonal MEDI3506 γ 1-chain), disulfide with human monoclonal MEDI3506 λ -chain, dimer (Source: CAS)
2. Immunoglobulin G1-lambda2, anti-[*Homo sapiens* IL33 (interleukin 33, DVS27, NF-HEV, IL1F11)], monoclonal antibody; gamma1 heavy chain (1-456) [VH (*Homo sapiens* IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (85.7%) L123>M (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-115) (1-126) -*Homo sapiens* IGHG1*03 (100%) G1m3, nG1m1 (CH1 R120 (223) (127-224), hinge 1-15 (225-239), CH2 (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-211')-disulfide with lambda2 light chain (1'-212') [V-LAMBDA (*Homo sapiens* IGLV3-1*01 (86.2%) -IGLJ2*01 (100%)) CDR-IMGT [6.3.9] (26-31.49-51.88-96) (1'-106') -*Homo sapiens* IGLC2*01 (100%) (107'-212')]; dimer (235-235":238-238")-bisdisulfide, produced in a Chinese hamster ovary (CHO) cell line derived from CHO-K1, glycoform alfa (Source: WHO PINN list 124)

STRUCTURAL FORMULA

Heavy chain

EVQLLESGGG	LVQPGGSLRL	SCAASGFTFS	SYAMSWVRQA	PGKGLEWVSG	50
ISAIQSTYY	ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYICARQK	100
FMQLWGGGLR	YDFGYWGQGT	MVTVSSASTK	GPSVFPLAPS	SKSTSGGTAA	150
LGCLVKDYFP	EPVTVSWNSG	ALTSGVHTFP	AVLQSSGLYS	LSSVVTVPSS	200
SLGTQTYICN	VNHKPSNTKV	DKRVEPKSCD	KHTTCPPCPA	PELLGGPSVF	250
LFPPPKPDTL	MISRTPEVTC	VVVDVSHEDP	EVKFNWYVDG	VEVHNAKTKP	300
REEQYNSTYR	VVSVLTVLHQ	DWLNKEYKC	KVSNKALPAP	IEKTISKAKG	350
QPREPQVYTL	PPSREEMTKN	QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY	400
KTTPPVLDSD	GSFFLYSKLT	VDKSRWQGN	VFSCSVMHEA	LHNHYTQKSL	450
SLSPGK					456

Light chain

SYVLTQPPSV	SVSPGQTASI	TCSGEGMGDK	YAAWYQKPG	QSPVLVIYRD	50
TKRPSGIPER	FSGSNSGNTA	TLTISGTQAM	DEADYICGVI	QDNTGVFGGG	100
TKLTVLQPK	AAPSVTLPFP	SSEELQANKA	TLVCLISDFY	PGAFTVANKA	150
DSSPVKAGVE	TTTPSKQSNN	KYAASSYLSL	TPEQWKSHRS	YSCQVTHEGS	200
TVEKTVAPTE	CS				212

Disulfide bridges

22-96	22''-96''	22'-87'	22'''-87'''	134'-193'	134'''-193'''	153-209	153''-209''
229-211'	229''-211'''	235-235''	238-238''	270-330	270'''-330'''	376-434	376''-434''

Glycosylation sites (N)

306	306''
-----	-------

MOLECULAR FORMULA

C₆₄₁₄H₉₉₅₆N₁₇₀₈O₂₀₀₆S₅₀

MOLECULAR WEIGHT	144.41 kDa
TRADEMARK	None as yet
SPONSOR	AstraZeneca
CODE DESIGNATIONS	MEDI3506
<u>CAS</u> REGISTRY NUMBER	2376858-66-9
UNII	OHZ2MEL7FD
WHO NUMBER	11647

gbk